Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1Breast 1

Conditions

Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 45pembrolizumab 35Magnetic Resonance Spectroscopy 32Specimen Handling 26Radiotherapy, Intensity-Modulated 21Cetuximab 18Nivolumab 17Carboplatin 16Platinum 151,2-diaminocyclohexaneplatinum II citrate 15Radiotherapy 13Biopsy 12Paclitaxel 10Gemcitabine 10Surveys and Questionnaires 9Radiation 9Docetaxel 9Immunoglobulin G 7Disulfides 7cemiplimab 6Ipilimumab 6Fluorouracil 6Bevacizumab 6toripalimab 5atezolizumab 5Watchful Waiting 5Taxes 5Immune Checkpoint Inhibitors 5Drug Therapy 5fludarabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
camrelizumab × Head & Neck × 30 days × Clear all
NCT05524168 2026-05-07

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
41 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡